Figure 1.
BAFF-R antibody sensitizes MCL cells to chemotherapy. (a) Flow cytometry analysis on three liquid MCL patient samples (Pt1, Pt2, and Pt3). Black histograms, control isotype; red histograms, anti-BAFFR 11c1. (b) BAFF-R expression in three MCL cell lines JVM2, Jeko-1, and Mino cells by flow cytometry. Black histograms, control isotype; red histograms, anti-BAFFR 11c1. (c) 1 × 105 Jeko-1 cells were seeded in 24-well plate in triplicates and cultured in the absence or presence of 200 ng/ml recombinant BAFF (rhBAFF) with or without 20 nM of cytarabine (CYT). The cell number was measured for the time indicated, not significant (ns) p > .05 for control Jeko-1 cells compared to rhBAFF-treated cells at day 5. ***p < .001 for Jeko-1 cells with cytarabine (CYT)+rhBAFF treatment compared with cells treated with CYT alone at day 7. One of the three experiments with triplicate samples shown. (d, left) 1 × 105 Jeko-1 cells or (e, left) Mino cells were seeded in 24-well plate in triplicates and cultured under different conditions such as untreated (ctrl) or 20 nM cytarabine (CYT), 5 μg/ml of neutralizing anti-BAFFR antibody (anti-BAFFR), CYT+anti-BAFFR antibody, and CYT+ anti-BAFFF-R antibody+200 ng/ml rhBAFF. The cell number was measured for the time indicated, ****p < .0001 Jeko-1 or Mino cells treated with anti BAFF-R antibody as compared to combined treatment of cytarabine and anti-BAFFR antibody. *p < .05 Jeko-1 cells treated with cytarabine+anti-BAFFR antibody compared to cytarabine+anti-BAFFR antibody+recombinant BAFF-treated Jeko-1 cells. *p < .05 for Jeko-1 cells treated with cytarabine versus combined treatment of cytarabine and anti-BAFFR antibody. Error bars are from single experiment done with triplicate samples representative of three such experiments done with triplicates